Overview

• The Journal of Nuclear Medicine reports that 64Cu-NOTA-EV-F(ab')2 selectively visualized nectin-4–positive tumors in preclinical studies.
• In triple-negative breast and urothelial bladder cancer xenografts, the tracer showed rapid accumulation with peak uptake at about four hours and high specificity.
• Compared with a full antibody conjugate (64Cu-NOTA-EV), the fragment achieved superior tumor-to-background contrast and faster clearance.
• The study integrated flow cytometry, immunofluorescence, cell uptake and binding assays, and immuno-PET biodistribution across models with different nectin-4 levels.
• Authors cite potential use for noninvasive patient stratification and real-time therapeutic monitoring with possibly lower radiation exposure, while emphasizing the work remains preclinical.